Effect of Probiotic Supplements on Osteoarthritis Outcomes

N/AActive Not RecruitingNCT06459700

Lund University86 enrolled

Overview

Dysbiosis of the gut microbiota is believed to contribute to the development and progression of osteoarthritis (OA), suggesting a role for probiotics in the treatment of OA. Animal studies have shown that certain probiotic strains decrease the inflammatory responses, pain sensitization and OA progression. There are, however, few clinical studies in humans to support this. In this double-blinded randomized controlled trial we will investigate the effect of 6-months probiotic supplements compared to placebo on OA related outcomes in females with diagnosed knee OA.

Aim: To investigate the effect of 6-months probiotic supplements compared to placebo on OA related outcomes in females with diagnosed knee OA. Design: Double-blinded randomized placebo controlled trial Study arms: One treatment arm will receive probiotic supplement in opaque white capsules and the other treatment arm will receive identical opaque placebo capsules. The placebo product will contain maize starch powder. Study participants will take one capsule daily for six months. Statistical analysis Main outcome: The independent T-test will be used to evaluate group differences in change in KOOS-12 scores between baseline and 6-months follow-up, given that all assumptions for parametric tests are satisfied. If assumptions are not met or if there are differences in baseline characteristics due to imbalanced randomization the Mann-Whitney U-test or regression analysis will be used as appropriate. Secondary and explorative outcomes: The independent T-test (continuous, normal distributed data), the Mann-Whitney U-test (ordinal, non-normally distributed data) and cross-tabulations with Chi2 test (nominal data) will be used to evaluate differences in secondary and explorative outcomes between the two groups. Estimated enrollment: 86 participants. Based on the ability to detect a 10-point difference in KOOS-12 with 80% power and α 0.05, 70 participants (35 per arm) will be needed. With an approximate drop-out rate of 20% from baseline to follow-up, 86 participants will be recruited. Investigators: Eva Ageberg, PT, PhD, Professor in physical therapy, Lund University, Sweden (Principal investigator), Anna Cronström, physical therapist, PhD, Lund University, Sweden and Jessica Neilands, PhD, Associate Professor, Science manager, Probi AB, Lund, Sweden.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

Conditions

Knee Osteoarthritis

Interventions

Probiotic supplementsDIETARY_SUPPLEMENT

See arm/group description

Placebo supplementsDIETARY_SUPPLEMENT

See arm/group description

Eligibility

Sex: FEMALEMin age: 45 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Females aged 45-70 years 2. Clinical diagnosis of knee OA 3. Mild to moderate knee joint pain (Visual Analog Scale (VAS) 3-7)) during the last 3 months 4. Able to perform walking and stair tests 5. No use of other supplements/food products containing probiotics and/or supplements targeting OA symptoms (e.g., glucosamine, turmeric) 6. Able to write and understand Swedish. Exclusion Criteria: 1. Rheumatoid arthritis or other active generalised inflammatory comorbidities affecting the gastrointestinal tract (IBD, celiac disease) 2. Performed a total knee replacement on the affected knee or on waiting list for joint replacement 3. Other concomitant injuries or surgeries overriding the OA knee symptoms 4. Other concomitant injuries or diseases where physical activity is a contra indication 5. Malabsorption disorders, presence of renal and/or hepatic failure 6. Use of corticosteroids with doses above 10 mg/day and/or Intra-articular injections during the previous 6 months 7. Heavy use of alcohol (\>10 standard units a week), or recreational drug use 8. BMI ≥30 Kg/m2 9. Antibiotic treatment during the previous 2 months 10. clinical depression diagnosis 11. Pregnancy/breast feeding 12. Smoking or other nicotine containing products during the previous 6months 13. Performed a gastric bypass 14. Immunosuppressive treatment or impaired immune system 15. Chronic or acute diarrhoea 16. Blood/plasma donation/transfusion during the 3months or during the study 17. Non-controlled diabetes 18. Allergy with regards to any of the study product ingredients.

Locations (1)

MoReLab, Lund University

Lund, Sweden

Outcomes

Primary Outcomes

Knee injury and Osteoarthritis Outcome Score (KOOS)-12

Change in the KOOS-12 (total score) from baseline to 6 months in the probiotic group compared with the placebo group. The KOOS-12 is scored from 1-100 (worst-best) scale.

Time frame: 6 months

Secondary Outcomes

Knee injury and Osteoarthritis Outcome Score (separate subscale score)

Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in Scores on the separate subscales (pain, symptoms, activity of daily living, sport/recreation and knee-related quality of life) from the full KOOS questionnaire. The KOOS is scored from 1-100 (worst-best) scale.

Time frame: 3 to 6 months

Visual Analogue Scale (VAS)

Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in VAS scores (pain severity), assessed on an ordinal scale from 0 to 10 where 0 indicates no pain and 10 worst possible pain the last week

Time frame: 3 to 6 months

Work Productivity and Activity Impairment questionnaire (WPAI)

Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in WPAI. The WPAI questionnaire includes 6 questions regarding employee's absenteeism, reduced job performance, work productivity loss, and activity impairment. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity, i.e., worse outcomes.

Time frame: 3 to 6 months

Patient Acceptable Symptom State (PASS)

Comparison of the probiotic group with the placebo group in terms of changes from baseline to 3-month and 6-month follow-up in PASS. The PASS involves a question regarding if the patient is satisfied with their current knee function with to response options (yes/no)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.